• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Katie Pfaff

Katie Pfaff

katie.pfaff@clarivate.com
Articles

ARTICLES

Speedx wins FDA clearance for M. genitalium, drug resistant STI, testing kit

April 20, 2018
By Katie Pfaff

Mauna Kea's Cellvizio twice as good at identifying esophageal cancer risk

April 19, 2018
By Katie Pfaff

Olympus acquires lithotripsy technology from Cybersonics

April 18, 2018
By Katie Pfaff

Boston Scientific buys Nvision for up to $275M in cash and milestones

April 17, 2018
By Katie Pfaff
Boston Scientific Corp. has acquired private firm and maker of FDA-approved fallopian tube cell collection device, Nvision Medical Corp., in a deal worth $275 million. The sale will include a $150 million cash payment and up to $125 million in clinical and commercial milestone payments across the next four years. The acquisition is not expected to impact Boston Scientific's bottom line through 2018 and 2019.
Read More

Allergan markets drug-free neurostim device for inadequate tears

April 16, 2018
By Katie Pfaff

Ivantis 'sees' IOP reduction in glaucoma patients with Hydrus stent on U.S. Horizon

April 13, 2018
By Katie Pfaff

Abbott enrolls first patient in trial of OCT vs. X-ray placement for Xience stent

April 12, 2018
By Katie Pfaff

Loxo, Illumina partner to co-develop pan-cancer Dx and targeted therapies

April 11, 2018
By Katie Pfaff

Loxo Oncology, Illumina partner to co-develop pan-cancer Dx and targeted therapies

April 11, 2018
By Katie Pfaff
Loxo Oncology Inc. and Illumina Inc. have struck up a strategic partnership to develop and commercially launch a multigene panel companion diagnostic (Cdx) for broad tumor profiling. The next-generation sequencing (NGS) diagnostic would carry a pan-cancer indication. The companies plan to pursue an approval for a variation of Illumina's Trusight Tumor 170 along with Loxo Oncology's therapies, larotrectinib and Loxo-292, which affect NTRK gene fusions and RET gene alterations, respectively.
Read More

Medtronic launches pivotal trial for Symplicity Spyral RDN system

April 10, 2018
By Katie Pfaff
Medtronic plc has received FDA IDE approval for a pivotal study of its Symplicity Spyral renal denervation (RDN) system in treatment of patients with hypertension. The trial, SPYRAL HTN, is being conducted as part of the firm's multi-phase Spyral HTN global clinical program, which seeks to evaluate the efficacy and safety of its RDN platform. Minimally invasive RDN procedures impact nerves in the kidney that regulate blood pressure, intending to decrease pressure among hypertensive patients. Symplicity Spyral is approved in 50 countries and is an investigational device in Japan and the U.S.
Read More
View All Articles by Katie Pfaff

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 29, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 29, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 27, 2025
  • 3d rendering of bispecific antibodies

    Pfizer bets $6B+ on 3Sbio’s bispecific PD-1/VEGF antibody

    BioWorld
    Pfizer Inc. is paying $1.25 billion up front and up to $4.8 billion in milestone payments to gain global, ex-China rights to SSGJ-707, a PD-1/VEGF bispecific...
  • KT-621: a first-in-class STAT6 degrader for Th2-driven diseases

    BioWorld Science
    STAT6 plays a central role in regulating Th2-driven immune responses. Recent studies have identified gain-of-function mutations in the STAT6 gene that are...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe